LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

AZN

81.26

-0.34%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

AZN

81.26

-0.34%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

AZN

81.26

-0.34%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

AZN

81.26

-0.34%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

AZN

81.26

-0.34%↓

Search

Rhythm Pharmaceuticals Inc

Geschlossen

BrancheGesundheitswesen

101.36 1.73

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

98.76

Max

101.36

Schlüsselkennzahlen

By Trading Economics

Einkommen

2.9M

-47M

Verkäufe

16M

49M

Gewinnspanne

-96.144

Angestellte

283

EBITDA

6.9M

-40M

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+12.34% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

4. Nov. 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

896M

6.9B

Vorheriger Eröffnungskurs

99.63

Vorheriger Schlusskurs

101.36

Nachrichtenstimmung

By Acuity

38%

62%

117 / 371 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Strong Bearish Evidence

Rhythm Pharmaceuticals Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

9. Sept. 2025, 23:37 UTC

Heiße Aktien

Stocks to Watch: Oracle, Wearable Devices, GameStop

9. Sept. 2025, 20:41 UTC

Ergebnisse

Oracle's Backlog Surges With Major Customer Deals in 1Q

9. Sept. 2025, 20:30 UTC

Ergebnisse

GameStop 2Q Sales, Profit Rise

9. Sept. 2025, 23:19 UTC

Market Talk

ANZ Adds a Further 50 Bps in FOMC Cuts to Outlook -- Market Talk

9. Sept. 2025, 21:35 UTC

Ergebnisse

Oracle Stock Soars on Strong AI Backlog. Earnings Were Good Enough. -- Barrons.com

9. Sept. 2025, 21:32 UTC

Ergebnisse

Oracle's Backlog Swells With Big Customer Deals -- Update

9. Sept. 2025, 21:02 UTC

Akquisitionen, Fusionen, Übernahmen

DHL Adds to Healthcare Logistics Services With Acquisition -- Update

9. Sept. 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

9. Sept. 2025, 20:33 UTC

Ergebnisse

These Stocks Moved the Most Today: Apple, UnitedHealth, Nebius, Wolfspeed, Tourmaline Bio, Albemarle, Dell, and More -- Barrons.com

9. Sept. 2025, 20:26 UTC

Ergebnisse

Oracle Stock Soars on Strong Backlog. Earnings Were Good Enough. -- Barrons.com

9. Sept. 2025, 20:23 UTC

Ergebnisse

Oracle Stock Soars on Strong Backlog. Earnings Were Good Enough. -- Barrons.com

9. Sept. 2025, 20:12 UTC

Ergebnisse

Oracle Stock Jumps on Mixed Earnings Report -- Barrons.com

9. Sept. 2025, 20:10 UTC

Ergebnisse

Oracle Expects Cloud Infrastructure Rev to Grow 77% to $18 B This Fiscal Yr >ORCL

9. Sept. 2025, 20:10 UTC

Ergebnisse

Oracle Expects to Sign-Up Several Additional Multi-B-dollar Customers and RPO Is Likely to Exceed Half-A-Trillion Dollars Over Next Few Mos

9. Sept. 2025, 20:09 UTC

Ergebnisse

Synopsys Sees 4Q Adj EPS $2.76-Adj EPS $2.80 >SNPS

9. Sept. 2025, 20:09 UTC

Ergebnisse

Synopsys Sees 4Q Loss/Shr 16c-Loss 27c >SNPS

9. Sept. 2025, 20:08 UTC

Ergebnisse

Oracle 1Q Short-term Deferred Rev Were $12.1 B >ORCL

9. Sept. 2025, 20:08 UTC

Ergebnisse

Oracle 1Q Operating Income Was $4.3 B >ORCL

9. Sept. 2025, 20:08 UTC

Ergebnisse

Oracle Expects MultiCloud Rev to Grow Substantially Every Qtr for Several Years >ORCL

9. Sept. 2025, 20:08 UTC

Ergebnisse

Synopsys Sees 4Q Rev $2.23B-$2.26B >SNPS

9. Sept. 2025, 20:07 UTC

Ergebnisse

Oracle Total Remaining Performance Obligations Up to $455 B >ORCL

9. Sept. 2025, 20:06 UTC

Ergebnisse

Oracle 1Q Software Revenue $5.72B >ORCL

9. Sept. 2025, 20:06 UTC

Ergebnisse

Synopsys 3Q Adj EPS $3.39 >SNPS

9. Sept. 2025, 20:06 UTC

Ergebnisse

Oracle 1Q Cloud Revenue $7.19B >ORCL

9. Sept. 2025, 20:05 UTC

Ergebnisse

Oracle 1Q Rev $14.93B >ORCL

9. Sept. 2025, 20:05 UTC

Ergebnisse

Oracle 1Q EPS $1.01 >ORCL

9. Sept. 2025, 20:05 UTC

Ergebnisse

Synopsys 3Q EPS $1.50 >SNPS

9. Sept. 2025, 20:05 UTC

Ergebnisse

Oracle 1Q Services Revenue $1.35B >ORCL

9. Sept. 2025, 20:05 UTC

Ergebnisse

Oracle 1Q Adj EPS $1.47 >ORCL

9. Sept. 2025, 20:05 UTC

Ergebnisse

Oracle 1Q Hardware Revenue $670M >ORCL

Peer-Vergleich

Kursveränderung

Rhythm Pharmaceuticals Inc Prognose

Kursziel

By TipRanks

12.34% Vorteil

12-Monats-Prognose

Durchschnitt 112.08 USD  12.34%

Hoch 135 USD

Tief 95 USD

Basierend auf 13 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Rhythm Pharmaceuticals Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

13 ratings

13

Buy

0

Halten

0

Sell

Technischer Score

By Trading Central

60 / 65.58Unterstützung & Widerstand

Kurzfristig

Strong Bearish Evidence

Mittelfristig

Bullish Evidence

Langfristig

Bullish Evidence

Stimmung

By Acuity

117 / 371 Ranking in Gesundheitswesen

Nachrichtenstimmung

Bullische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Rhythm Pharmaceuticals Inc

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; joint research collaboration with Axovia Therapeutics for developing in bardet-biedl syndrome; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
help-icon Live chat